INSIGHTEC’s non-invasive MR-guided focused ultrasound (MRgFUS) technology was first applied in the Women’s Health field more than 15 years ago and today continues to be used to treat symptomatic uterine fibroids and adenomyosis.

 Focused ultrasound waves, guided by MRI (magnetic resonance imaging) safely ablate the target tissue, ensuring a high rate of effectiveness with minimal side effects. The procedure is called Curawave, and it is usually performed on an outpatient basis.

 Curawave is incision-less and leaves no scars unlike the most common procedure for treating symptomatic uterine fibroids, hysterectomy. Following the Curawave procedure, patients are able to return to work and normal activity within days. Furthermore, Curawave is uterine-sparing.

 *Khan AT, Shehmar M, Gupta JK Uterine fibroids: current perspectives Int J Womens Health. 2014; 6: 95–114. doi: 10.2147/IJWH.S51083; Day Baird D, Dunson DB, Hill MC, Cousins D, Schectman JM: High cumulative incidence of uterine leiomyoma in black and white women: ultrasound evidence. Am J Obstet Gynecol 2003, 188(1):100–107 ** Fibroidrelief.org, survey of 968 women between 2011 and 2012

 

 

 

 

 

Downloads

How it works

Non-invasive MRgFUS Treatment of Uterine Fibroids and Adenomyosis

    • Uterine Fibroids
      Read More close

Why Insightec Women's Health?

  • CLINICAL VALUE

    Curawave is a non-invasive treatment option that demonstrates symptom relief with a low rate of adverse events. Furthermore, it provides the ability to verify the ablation coverage of the fibroid immediately post-procedure.

  • PATIENT VALUE

    When given a choice, many women patients will opt for a non-invasive and uterine-preserving treatment. The Curawave procedure provides patients with a short recovery and rapid return to daily activities.

  • ECONOMIC VALUE

    By offering Curawave as a non-invasive treatment option, medical centers are able to broaden their service offering to attract new patients.

Physician Testimonials

Dr. Jaron Rabinovici states, “Uterine Fibroids are the most common tumor of the female pelvis, causing women to seek the ultimate treatment for their symptoms. Exablate MRgFUS gives the woman a choice to have a much better, efficacious, treatment for uterine fibroids than surgery".

Dr. Med. Matthias Matzko, of Helios Amper Hospital in Dachau, Germany speaks about the many advantages Exablate MRgFUS has to offer for both radiologists and patients, and the role of image guided procedures play in the future of medicine.

Regulatory Approvals

Per Indication
  • Uterine Fibroids

  • Adenomyosis

Please fill all the following details and we get in touch with you (* Required)

agreement Error

Thank You!

Thank you for contacting us! We will get back to you shortly.

Thank You!

This site is brought to you by INSIGHTEC, © 2017 INSIGHTEC Ltd. All rights reserved

NGSoft logo